Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Congenital FXIII Deficiency
Intervention: Drug: recombinant factor XIII
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Conditions: Breast Cancer; Hot Flashes; Menopausal Symptoms; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: flaxseed; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: capecitabine; Drug: sunitinib malate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gabapentin; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: pemetrexed disodium; Genetic: gene expression analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cladribine; Drug: temsirolimus; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Other: clinical observation; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: gemcitabine hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsor: Gentium SpA
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
Interventions: Biological: infliximab; Drug: conventional systemic agents; Biological: Biological therapies other than infliximab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: capecitabine; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid sequencing; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: computed tomography; Procedure: single photon emission computed tomography; Radiation: 3-dimensional conformal radiation therapy; Radiation: fludeoxyglucose F 18; Radiation: intensity-modulated radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: docetaxel; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin; Other: clinical observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: denileukin diftitox; Biological: rituximab; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Small Intestine Cancer
Interventions: Drug: capecitabine; Drug: irinotecan hydrochloride; Drug: oxaliplatin
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
Interventions: Drug: motesanib diphosphate; Drug: octreotide acetate; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Procedure: computed tomography
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: dasatinib; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: immunologic technique; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Conditions: Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma
Interventions: Dietary Supplement: glutamic acid; Other: placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); Children's Oncology Group
Recruiting - verified February 2010
Condition: Kidney Cancer
Intervention: Biological: aflibercept
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: entinostat
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: pentostatin
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: imatinib mesylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010